Editorial board member, Eleni Andreopoulou, from Weill Cornell Medical College in New York, US, discusses molecular subtyping and advances in molecularly-targeted therapy in triple-negative breast cancer.
Q1. What are the major challenges of treating triple-negative breast cancer? (0:11)
Q2. How have advances in molecular subtyping impacted on the treatment of triple negative-breast cancer? (1:50)
Q3. What unmet needs remain in molecularly targeted breast cancer therapy? (2:36)
Q4. What innovations in clinical trial design are facilitating the development of therapies for high-risk, early-stage breast cancer? (3:41)
Speaker disclosures: Eleni Andreopoulou has nothing to disclose in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
Share this Video
Related Videos In Breast Cancer
Javier Cortes, SABCS 2020 – Pembrolizumab in Triple-negative Breast Cancer
touchONCOLOGY joins Dr Javier Cortes at the San Antonio Breast Cancer Symposium (SABCS) 2020, to discuss the data being presented around the KEYNOTE-355 study and the potential of pembrolizumab as a treatment for triple-negative breast cancer (Clinical Trial Identifier: NCT02819518). The abstract ‘Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy […]
Janine Simons, SABCS 2020 – Radioactive Iodine Seed Localisation in the Axilla with the Sentinel Node Procedure: The RISAS Trial
We had the pleasure to talk to Janine Simons (Erasmus University Medical Center, Rotterdam, Netherlands) about the RISAS study and its findings (Clinical Trial Identifier: NCT02800317). The abstract ‘Radioactive Iodine Seed placement in the Axilla with Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer: Results of the prospective multicenter RISAS trial‘ (ABSTRACT NUMBER: […]
Leisha A Emens, ESMO 2020 – Overall Survival Analysis from IMpassion 130 in Triple-negative Breast Cancer
Prof. Leisha A Emens joins touchONCOLOGY to discuss the final overall survival analysis of the phase III IMpassion 130 study investigating atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Prof. Emens explores what we can learn from these findings, as well as the failure of IMpassion […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!